Interstitial Cystitis / Bladder Pain Syndrome: factors predicting the clinical course of the disease

Introduction. Etiology of the Bladder pain syndrome/Interstitial cystitis (BPS/IC) remains completely unknown. BPS/ IC is a chronic disease in which bladder biopsy specimens show varying degrees of inflammation`s severity, detrusor fibrosis and mastocytosis. With BPS/IC, cellular mechanisms of inflammation and processes leading to tissue damage and fibrosis are still not entirely clear. However, the results of studies have shown that fibrosis and mastocytosis of the detrusor are associated with the need for various types of treatment and suggest the failure of standard therapy.

Purpose of research. The aim of the study is to determine the relationship between the anatomical capacity of the bladder and detrusor fibrosis with the clinical course of BPS/IC.

Materials and methods. 110 patients with BPS/IC were examined from 2010 to 2014 in the University Urological Clinic MSMU, A.I. Evdokimov Moscow State University of Medicine and Dentistry. Patients` pain severity was assessed by a 10-point Visual Analogue Pain scale (VAS). Clinical manifestations of the disease were assessed using international questionnaires: an index of symptoms and quality of life of patients with interstitial cystitis (Interstitial Cystitis Symptom and Problem Indexes; ICSI, ICPI) and scales of symptoms of pelvic pain, urgency and frequency of urination (the Urine and Frequency Questionnaire, PUF), Female Sexual Dysfunction Index (FSDI), Hospital Anxiety and Depression Scale. All patients underwent cystoscopy with general anesthesia for therapeutic and diagnostic purposes. Bladder biopsy was performed in 36 patients (33%) for the treatment of other bladder`s diseases, as well as for the degree`s pathological assessment of the inflammatory process and the severity of detrusor fibrosis.

Results. In 65% of patients, the anatomical capacity of the bladder was 200-350 ml, and in 5% of cases, its reduction to 100 ml was found. The average capacity of the bladder was 297 ± 90.2 ml. The results of the study suggest a significant decrease in the anatomical capacity of the bladder due to progressive inflammation and fibrosis in the bladder`s wall an essential factor affecting the clinical course of the BPS/IC, causing the severity of the organ-specific symptoms of the disease. A direct correlation was found between the indicators of the nature of alterative changes in urothelia, the severity of inflammatory infiltration and the severity of pain, symptoms of dysuria, in particular, frequency of urination and imperative urges, quality of life and mental health. The severity of fibrosis, the presence of perineuritis and mastocytosis are directly dependent on the duration of the disease.

Conclusions. Reduced bladder capacity and detrusor fibrosis are markers of bladder damage in BPS/IC. These changes are characteristic of a certain patients` subgroup who require endovesical treatment, unlike patients with a systemic phenotype and comorbid conditions.

1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnos c criteria, classifi ca on, and nomenclature for painful bladder syndrome ⁄ inters al cys s: an ESSIC proposal. Eur. Urol. 2008;53(1);60–67. DOI: 10.1016/j.eururo.2007.09.019

2. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(Suppl.4); 34–40. DOI: 10.1016/j.urology.2006.08.1109

3. Forrest JB, Moldwin R. Diagnostic options for early identification and management of interstitial cystitis ⁄ painful bladder syndrome. Int. J. Clin. Pract. 2008;62(12);1926– 1934. DOI: 10.1111/j.1742-1241.2008.01931.x

4. Richter B, Hesse U, Hansen AB, Horn T, Mortensen SO, Nordling J. Bladder pain syndrome ⁄ interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis. BJU Int. 2010;105(5); 660–667. DOI: 10.1111/j.1464410X.2009.08847.x

5. AUA Clinical Guidelines. Diagnosis and Treatment Interstitial Cystitis/Bladder Pain Syndrome. Published 2011; Amended 2014. Access mode: https://www.auanet.org/guidelines/ interstitial-cystitis/bladder-pain-syndrome-(2011amended- 2014)

6. Zaitsev A., Pushkar DYu, Korsunskaya IL, Kovylina MV, Tsybulya OA. Modern aspects of diagnosis and treatment of painful bladder syndrome / inters al cys s. RMJ. 2010; 18 (381); 1084-1089. (In Russ.)

7. Pushkar DYu, Zaitsev AV, Kovylina MV, Tsybulya OA, Vasilyev AO. Urothelial Histomorphology in inflammatory diseases of the bladder. Bulletin of Volgograd State Medical University. 2011;2:94-97.(In Russ.)

8. Pushkar DYu, Zaitsev AV. Longidase in the treatment of patients with interstitial cystitis. Urologiia. 2007; 5: 35-37. (In Russ.)

9. Kovylina MV, Zaytsev AV, Ibragimov RA, Korsunskaya IL. Enzymatic drugs for combination treatment of painful bladder syndrome/interstitial cystitis. Effective Pharmacotherapy. Urology and Nephrology. 2013;2 (16): 8-12. (In Russ.)

10. WHO Drug Information Vol. 29, No. 3, 2015 - Recommended International Nonproprietary Names, List 74. (2015; 130 pages) Access mode: http://apps.who.int/medicinedocs/en/m/abstract/Js22124en/

11. Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, Walker SJ. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J Urol. 2014;192(4):1123-1129. DOI: 10.1016/j.juro.2014.05.047

12. Griffith JW, Stephens-Shields AJ, Hou X, Naliboff BD, Pontari M, Edwards TC, Williams DA, Clemens JQ, Afari N, Tu F, Lloyd RB, Patrick DL, Mullins C, Kusek JW, Sutcliffe S, Hong BA, Lai HH, Krieger JN, Bradley CS, Kim J, Landis JR. Pain and urinary symptoms should not be combined into a single score: psychometric findings from the MAPP Research Network. J Urol. 2016;195(4P1):949-954. DOI: 10.1016/j. juro.2015.11.012

13. Chuang YC, Weng SF, Hsu YW, et al. Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/ interstitial cystitis: a nationwide population-based study. Int Urol Nephrol. 2015;47(2):275-281. DOI: 10.1007/s11255014-0908-6

14. Krieger JN, Stephens AJ, Landis JR, Clemens JQ, Kreder K, Lai HH, Afari N, Rodríguez L, Schaeff er A, Mackey S, Andriole GL, Williams DA; MAPP Research Network. Rela onship between chronic nonurological associated soma c syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evalua on of the MAPP study. J Urol. 2015;193(4):1254-1262. DOI: 10.1016/j.juro.2014.10.086

15. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chi nase-like lec n, YKL-40, binds specifi cally to type I collagen and modulates the rate of type I collagen fi bril forma on. J. Biol. Chem. 2006;281(30);21082–21095. DOI: 10.1074/jbc.M601153200

16. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with infl amma on, ssue remodelling, fi brosis and cancer. Dan. Med. Bull. 2006;53(2);172–209. PMID: 17087877

17. Letuve S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M. YKL-40 is elevated in pa ents with chronic obstruc ve pulmonary disease and ac vates alveolar macrophages. J. Immunol. 2008; 181(7); 5167–5173. DOI: 10.4049/jimmunol.181.7.5167